Notoginsenoside R1
(Synonyms: 三七皂甙R1,Sanchinoside R1; Sanqi glucoside R1) 目录号 : GN10695
Notoginsenoside R1一种从Panax notoginseng中分离得到的主要活性皂苷成分，是多种中药制剂的关键生物活性化合物。
Cas No.:80418-24-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Notoginsenoside R1 is a major active saponin component isolated from Panax notoginseng and is a key bioactive compound in many traditional Chinese medicine formulations[1]. Notoginsenoside R1 can improve the recovery of neurological function following cerebral ischemia-reperfusion injury[2]. Notoginsenoside R1 can be used to study its protective effects on vascular endothelial cells and nerve cells[3]. Notoginsenoside R1 also has potential pharmacological activities in improving cardiac repair after myocardial infarction, alleviating cognitive deficits in a diabetes-induced Alzheimer's disease model, and regulating glucose and lipid metabolism[4].
In vitro, treatment of hepatocellular carcinoma cell lines HepG2 and MHCC97H with Notoginsenoside R1 (0-150μM) for 72 hours significantly reduced cell viability and induced an increase in caspase-3 activity, indicating Notoginsenoside R1 promotion of tumor cell apoptosis[5]. Pretreatment of H9C2 cardiomyocytes and primary cardiomyocytes with Notoginsenoside R1 (100μM) for 30 minutes, followed by treatment with H₂O₂ (350μM) or oxygen-glucose deprivation (OGD), significantly inhibited the accumulation of reactive oxygen species (ROS) and mitochondrial superoxide generation, while also reducing cell apoptosis[6].
In vivo, oral pretreatment of neonatal rats with Notoginsenoside R1 (12.5-50mg/kg) from postnatal day 2 to day 7, followed by exposure to 3% sevoflurane for 6 hours, significantly reduced neuronal apoptosis in the CA1, CA3, and DG regions of the hippocampus[7]. Intraperitoneal injection of Notoginsenoside R1 (25mg/kg) 30 minutes before myocardial ischemia (every 2 hours; a total of 3 times) significantly reduced the myocardial infarction area and decreased the levels of plasma myocardial injury markers cTnI and CK-MB[8].
References:
[1] Guo S, Xi X, Li J. Notoginsenoside R1: A systematic review of its pharmacological properties. Pharmazie. 2019 Nov 1;74(11):641-647.
[2] Tong Q, Zhu PC, Zhuang Z, et al. Notoginsenoside R1 for Organs Ischemia/Reperfusion Injury: A Preclinical Systematic Review. Front Pharmacol. 2019 Oct 17;10:1204.
[3] Zhu T, Xie WJ, Wang L, et al. Notoginsenoside R1 activates the NAMPT-NAD+-SIRT1 cascade to promote postischemic angiogenesis by modulating Notch signaling. Biomed Pharmacother. 2021 Aug;140:111693.
[4] Wen C, Liao X, Ye X, et al. Pharmacokinetics and Biological Activities of Notoginsenoside R1: A Systematical Review. Am J Chin Med. 2025;53(1):205-249.
[5] Li H, Zhu J, Xu YW, et al. Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction. Redox Biol. 2022 Aug;54:102384.
[6] Li H, Zhu J, Xu YW, et al. Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction. Redox Biol. 2022 Aug;54:10238.
[7] Zhang Y, Zhao Y, Ran Y, et al. Notoginsenoside R1 attenuates sevoflurane-induced neurotoxicity. Transl Neurosci. 2020 Jun 22;11(1):215-226.
[8] Zeng JJ, Shi HQ, Ren FF, et al. Notoginsenoside R1 protects against myocardial ischemia/reperfusion injury in mice via suppressing TAK1-JNK/p38 signaling. Acta Pharmacol Sin. 2023 Jul;44(7):1366-1379.
Notoginsenoside R1一种从Panax notoginseng中分离得到的主要活性皂苷成分，是多种中药制剂的关键生物活性化合物[1]。Notoginsenoside R1可改善脑缺血再灌注损伤后的神经功能恢复[2]。Notoginsenoside R1可用于研究其对血管内皮细胞和神经细胞的保护作用[3]。Notoginsenoside R1还具有改善心肌梗死后的心脏修复、减轻糖尿病阿尔茨海默病模型中的认知缺陷以及调节糖脂代谢的潜在药理活性[4]。
在体外，Notoginsenoside R1（0-150μM）处理肝癌细胞系HepG2和MHCC97H 72小时，显著降低细胞活力并诱导caspase-3活性升高，表明其促进肿瘤细胞凋亡[5]。Notoginsenoside R1（100μM）预处理H9C2心肌细胞及原代心肌细胞30分钟，随后以H₂O₂（350μM）或氧糖剥夺（OGD）处理，显著抑制活性氧（ROS）积累和线粒体超氧化物生成，同时减少细胞凋亡[6]。
在体内，Notoginsenoside R1（12.5-50mg/kg）从出生后第2天至第7天口服预处理新生大鼠，随后以3%七氟醚暴露6小时，Notoginsenoside R1显著减轻海马CA1、CA3和DG区域的神经元凋亡[7]。Notoginsenoside R1（25mg/kg）于心肌缺血前30分钟开始腹腔注射（每2小时一次；共3次），Notoginsenoside R1显著降低心肌梗死面积，并降低血浆心肌损伤标志物cTnI和CK-MB水平[8]。
| Cell experiment [1]: | |
Cell lines | HepG2 and MHCC97H cells (human hepatocellular carcinoma cell lines) |
Preparation Method | Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were treated with Notoginsenoside R1 at concentrations of 0–150μM for 72 hours. |
Reaction Conditions | 0–150μM; 72h |
Applications | Notoginsenoside R1 significantly reduced cell viability in a dose-dependent manner and increased caspase-3 activity, indicating induction of apoptosis in hepatocellular carcinoma cells. |
| Animal experiment [2]: | |
Animal models | C57/BL6 mice |
Preparation Method | Mice were subjected to myocardial ischemia/reperfusion (MI/R) injury by occluding the left anterior descending coronary artery (LAD) for 30min followed by 4h reperfusion. Notoginsenoside R1 (25mg/kg, dissolved in normal saline) was intraperitoneally injected three times, starting 30min prior to ischemic surgery. |
Dosage form | 25mg/kg; i.p. |
Applications | Notoginsenoside R1 significantly reduced myocardial infarction area, lowered plasma cardiac troponin-I (cTnI) and creatine kinase-MB (CK-MB) levels, and decreased TUNEL-positive apoptotic cells in the infarct border zone. |
References: | |
| Cas No. | 80418-24-2 | SDF | |
| 别名 | 三七皂甙R1,Sanchinoside R1; Sanqi glucoside R1 | ||
| 化学名 | Notoginsenoside R1 | ||
| Canonical SMILES | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(CO6)O)O)O)C)O)C)OC7C(C(C(C(O7)CO)O)O)O)C | ||
| 分子式 | C47H80O18 | 分子量 | 933.13 |
| 溶解度 | DMF: 15 mg/ml,DMSO: 10 mg/ml,Ethanol: 0.1 mg/ml,PBS (pH 7.2): 1 mg/ml | 储存条件 | Store at -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.0717 mL | 5.3583 mL | 10.7166 mL |
| 5 mM | 214.3 μL | 1.0717 mL | 2.1433 mL |
| 10 mM | 107.2 μL | 535.8 μL | 1.0717 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet